Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age : AIDS

Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid
CLINICAL SCIENCE

Impact of CYP2B6 genotype, tuberculosis therapy, and formulation on efavirenz pharmacokinetics in infants and children under 40 months of age

Nikanjam, Minaa; Tran, Lanab; Chadwick, Ellen G.c; Bwakura-Dangarembizi, Mutsad; Bolton Moore, Carolyne,g; Samson, Pearlh; Spector, Stephen A.a; Chakhtoura, Nahidai; Jean-Philippe, Patrickf; Frenkel, Lisaj; Zimmer, Bonniek; Benns, Alexk; Libous, Jenniferl; Capparelli, Edmund V.a

Author Information
doi: 10.1097/QAD.0000000000003141
  • Buy
  • SDC

Abstract

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.